Assessing AlloSure Dd-cfDNA Monitoring Insights of Renal Allografts With Longitudinal Surveillance (ADMIRAL)

CareDx

Status: Unknown

Conditions: Kidney Transplant Rejection

Treatments: Device: AlloSure

Study type: Observational

Funder types: Industry

Identifiers

NCT04566055

ADMIRAL

Details and patient eligibility

About

Prospective Observational Multicenter Cohort. External validation of donor derived cell free DNA in Renal Transplantation. Assessing performance of dd-cfDNA as a surveillance tool and its association with clinical outcomes. Outcomes include formation of de-novo DSA, eGFR decline, performance of AlloSure dd-cfDNA in Allograft rejection.

Enrollment: 1,000 patients

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Renal transplant patients

Trial design

1,000 participants in 1 patient group

Prospective observational cohort

Treatment:

Device: AlloSure